Emerging evidence also suggests that SBRT may delay the onset of acquired resistance to EGFR-TKIs and prolong survival in EGFR-mutant NSCLC, supporting its integration into multimodal treatment strategies [50]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.